174 related articles for article (PubMed ID: 35652551)
1. Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Mengato D; Cancanelli L; Di Spazio L; Rivano M; Chiumente M; Messori A
Int J Clin Pharmacol Ther; 2022 Aug; 60(8):370-372. PubMed ID: 35652551
[No Abstract] [Full Text] [Related]
2. Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC; Coleman RL; Westin SN
Curr Treat Options Oncol; 2018 Nov; 19(12):1. PubMed ID: 30535808
[TBL] [Abstract][Full Text] [Related]
3. Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction: A Case Report.
Endo Y; Kamo N; Kato A; Sato T; Okabe C; Furukawa S; Watanabe T; Soeda S
In Vivo; 2024; 38(2):958-962. PubMed ID: 38418162
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
5. Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.
Neeser K; O'Neil WM; Stern L; Harrow B; Travers K
J Comp Eff Res; 2019 Jun; 8(8):577-587. PubMed ID: 30935213
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE; Bai J; Moore KN; Kristeleit R; Monk BJ; Tewari KS
Gynecol Oncol; 2020 May; 157(2):500-507. PubMed ID: 32173049
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
8. Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Wang L; Wang Q; Xu Y; Cui M; Han L
Curr Drug Targets; 2020; 21(2):167-178. PubMed ID: 31553293
[TBL] [Abstract][Full Text] [Related]
9. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer.
Kim JH; Kim SI; Park EY; Kim ET; Kim H; Kim S; Park SY; Lim MC
Gynecol Oncol; 2024 Feb; 181():33-39. PubMed ID: 38104527
[TBL] [Abstract][Full Text] [Related]
10. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Zhong L; Tran AT; Tomasino T; Nugent E; Smith JA
J Manag Care Spec Pharm; 2018 Dec; 24(12):1219-1228. PubMed ID: 30479195
[TBL] [Abstract][Full Text] [Related]
12. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review.
Borrelli EP; McGladrigan CG
J Oncol Pharm Pract; 2020 Dec; 26(8):1977-1986. PubMed ID: 32659172
[TBL] [Abstract][Full Text] [Related]
13. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
[TBL] [Abstract][Full Text] [Related]
14. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Jiang X; Li X; Li W; Bai H; Zhang Z
J Cell Mol Med; 2019 Apr; 23(4):2303-2313. PubMed ID: 30672100
[TBL] [Abstract][Full Text] [Related]
15. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.
Cancanelli L; Mengato D; Di Spazio L; Rivano M; Chiumente M; Messori A
Int J Clin Pharmacol Ther; 2022 Jan; 60(1):32-35. PubMed ID: 34779394
[TBL] [Abstract][Full Text] [Related]
17. Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Kerliu L; Myruski S; Bhatti A; Soni P; Petrosius P; Pervanas HC; Horton ER
Ann Pharmacother; 2020 Oct; 54(10):1010-1015. PubMed ID: 32172572
[TBL] [Abstract][Full Text] [Related]
18. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
19. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Moore KN; Mirza MR; Matulonis UA
Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors for ovarian cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):200-202. PubMed ID: 29186085
[No Abstract] [Full Text] [Related]
[Next] [New Search]
